Medacta Group Sa Stock Net Income

MEDGF Stock  USD 83.91  0.00  0.00%   
In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Medacta Group SA, as well as the relationship between them.
Medacta Group's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Medacta Group's valuation are provided below:
Medacta Group SA does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Understanding that Medacta Group's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Medacta Group represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Medacta Group's market price signifies the transaction level at which participants voluntarily complete trades.

Medacta Group 'What if' Analysis

In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Medacta Group's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Medacta Group.
0.00
11/16/2025
No Change 0.00  0.0 
In 3 months and 1 day
02/14/2026
0.00
If you would invest  0.00  in Medacta Group on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Medacta Group SA or generate 0.0% return on investment in Medacta Group over 90 days. Medacta Group is related to or competes with Sanofi, CSL, GSK Plc, Fresenius, Sonova Holding, Essilor International, and EssilorLuxottica. Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Europe, North Amer... More

Medacta Group Upside/Downside Indicators

Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Medacta Group's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Medacta Group SA upside and downside potential and time the market with a certain degree of confidence.

Medacta Group Market Risk Indicators

Today, many novice investors tend to focus exclusively on investment returns with little concern for Medacta Group's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Medacta Group's standard deviation. In reality, there are many statistical measures that can use Medacta Group historical prices to predict the future Medacta Group's volatility.
Hype
Prediction
LowEstimatedHigh
83.9183.9183.91
Details
Intrinsic
Valuation
LowRealHigh
83.9183.9183.91
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Medacta Group. Your research has to be compared to or analyzed against Medacta Group's peers to derive any actionable benefits. When done correctly, Medacta Group's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Medacta Group SA.

Medacta Group SA Backtested Returns

We have found three technical indicators for Medacta Group, which you can use to evaluate the volatility of the firm. The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Medacta Group are completely uncorrelated.

Auto-correlation

    
  1.00  

Perfect predictability

Medacta Group SA has perfect predictability. Overlapping area represents the amount of predictability between Medacta Group time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Medacta Group SA price movement. The serial correlation of 1.0 indicates that 100.0% of current Medacta Group price fluctuation can be explain by its past prices.
Correlation Coefficient1.0
Spearman Rank Test1.0
Residual Average0.0
Price Variance0.0
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Based on the recorded statements, Medacta Group SA reported net income of 51.52 M. This is 84.9% lower than that of the Healthcare sector and 78.36% lower than that of the Medical Devices industry. The net income for all United States stocks is 90.98% higher than that of the company.

Medacta Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medacta Group's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Medacta Group could also be used in its relative valuation, which is a method of valuing Medacta Group by comparing valuation metrics of similar companies.
Medacta Group is currently under evaluation in net income category among its peers.

Medacta Fundamentals

About Medacta Group Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Medacta Group SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medacta Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medacta Group SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Medacta Pink Sheet

Medacta Group financial ratios help investors to determine whether Medacta Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medacta with respect to the benefits of owning Medacta Group security.